CA-PROLIFIC-MACHINES
14.9.2022 15:34:41 CEST | Business Wire | Press release
Prolific Machines, a next generation biotechnology company, is emerging from stealth today by announcing their massively oversubscribed Seed and Series A financings, led by the best VCs in the space. The Seed round was led by Arvind Gupta at Mayfield, the first investor in cultured meat. The Series A was led by Bill Gates-founded Breakthrough Energy Ventures. Prolific’s first check was written in late 2020, when SOSV’s IndieBio led their Pre-Seed round.
The lead VCs were joined by a number of high profile co-investors such as David Adelman, Mark Cuban (owner of the Dallas Mavericks), The Kraft Group (owners of the New England Patriots), David Rubenstein, Michael Rubin, Breyer Capital, The SALT Fund, Purple Orange Ventures, Fred Blackford, Jake Poliskin, and Baruch Future Ventures. A number of celebrities and restaurateurs have also invested in Prolific including: Kevin Love, Tobias Harris, Meek Mill, Ciara & Russell Wilson, Emily Ratajkowski, Maverick Carter, Sean Feeney, Michael Schulson, Mark Bucher, and RJ Melman.
Prolific is unique in that they are inventing the scalable manufacturing process first, and a product second. This is very different to the path taken by other cultured meat companies. Prolific aims to do for biology what Henry Ford did for automobiles. In 1906, there were hundreds of car companies, yet most people could not afford a car. After Ford invented the assembly line for automobiles, car production became scalable, and then cars became a mass market item. Prolific is inventing the technology that holds the key to building a scalable assembly line for biology.
Dr. Deniz Kent, Co-founder and CEO of Prolific Machines, started the company after witnessing the Syrian refugee crisis in his hometown of Antioch, Turkey. He realized that what he experienced would be nothing compared to the impending global refugee crises caused by climate change. He knew his expertise in stem cell biology could be used to create a sustainable food system, but lacked confidence in the ability of existing technologies to compete with factory farming on cost. He conceived of a new way to grow and control cells without the need for any recombinant proteins, the most expensive ingredients in cell production. He spent three years searching for the perfect co-founders while the idea marinated in his mind. He eventually found a brilliant physicist Dr. Max Huisman, and an exceptional machine learning engineer Declan Jones. Deniz convinced them to quit their jobs, and together they assembled an all-star team to embark upon a journey to revolutionize biomanufacturing.
“We are of the opinion that existing technologies being deployed in cultured meat will not reach price parity with factory farming. A fundamentally new approach is going to be required. We are inventing this new approach, and I'm open to making our technology available to every meat company. Our mission is to address the existential risks posed by our changing climate, and we have no time to waste,” said Deniz.
Arvind Gupta, partner at Mayfield and first investor in many prominent food companies, says of the Seed round, “I never intended to invest in another cultured meat company. But when Deniz showed me what they were doing, I was blown away by the creativity in their approach to reinvent the assembly line for food production. It is my goal to help reverse climate change by partnering with incredible teams, and I am convinced Prolific Machines will be a winner in the race for sustainable food production.”
After making quick progress, Breakthrough Energy Ventures met the team and was similarly impressed. “Prior to meeting Prolific we had come to the conclusion that a fundamental breakthrough would be required for cultured meat to be economically competitive with conventional meat production,” said Carmichael Roberts, Breakthrough Energy Ventures. “We believe that Prolific Machines may be this breakthrough. Prolific’s novel technology has the potential to enable the cost-competitive production of high-quality cultured meat products and they have the team to execute it."
Po Bronson, Managing Director at IndieBio and General Partner at SOSV, was the first to recognise Prolific’s potential. He wrote the Pre-Seed check, and incubated them from IndieBio while they de-risked their early science. “Prolific was a radical idea with a truly incredible team, exactly what IndieBio loves. Prolific has broken all of the records at IndieBio, and I see their technology as the best in this space.”
Deniz explains the next steps. “We are building a 25,000 square foot HQ in Emeryville and ramping up hiring to expand our assembly line programs, including fish, poultry, and beef. If you are talented and looking to make a historic change, come and talk to us.”
If you would like to support us, you can join the waitlist and find out more information at www.prolific-machines.com.
About Prolific Machines
Prolific Machines is a biomanufacturing company inventing novel technologies to grow and differentiate stem cells at a dramatically lower cost relative to conventional means. The initial focus of the company is cultured meat, but the technology they are developing is cell-agnostic, meaning that it could be applied to myriad of different applications in biotechnology. Further information is available at www.prolific-machines.com, and you can stay updated by following the company on LinkedIn.
About Breakthrough Energy Ventures
Founded by Bill Gates and backed by many of the world’s top business leaders, BEV has raised more than $2 billion in committed capital to support cutting-edge companies that are leading the world to net-zero emissions. BEV is a purpose-built investment firm that is seeking to invest, launch and scale global companies that will eliminate GHG emissions throughout the economy as soon as possible. BEV seeks true breakthroughs and is committed to supporting these entrepreneurs and companies by bringing to bear a unique combination of technical, operational, market and policy expertise.
BEV is a part of Breakthrough Energy, a network of investment vehicles, philanthropic programs, policy advocacy, and other activities committed to scaling the technologies we need to reach net-zero emissions by 2050. Visit www.breakthroughenergy.org to learn more.
About Mayfield
Mayfield is a global venture capital firm with a people-first philosophy and a 50+ year track record of inception and early-stage investing, partnering with founders to build iconic enterprise, consumer and engineering biology companies. Since its founding, the firm has invested in more than 500 companies, resulting in 120 IPOs and more than 200 acquisitions, and currently has $2.2B under management. For more information, go to https://www.mayfield.com or follow @MayfieldFund.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
